

PRECEPTORSHIP PROGRAMME

Immuno-Oncology

From the essentials of tumour
immunology to clinical application

LUGANO
SWITZERLAND

4-5 MAY 2018

Co-Chairs John B.A.G. Haanen, NL
 Solange Peters, CH
 Rolf A. Stahel, CH

ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

Lugano, Switzerland
4-5 May 2018

CO-CHAIRS:

John B.A.G. Haanen, Netherlands
Solange Peters, Switzerland
Rolf A. Stahel, Switzerland

SPEAKERS:

Andrés Cervantes, Spain	Pedro Romero, Switzerland
Giuseppe Curigliano, Italy	Cristiana Sessa, Switzerland
Markus G. Manz, Switzerland	Inge-Marie Svane, Denmark
Aurélien Marabelle, France	Michiel S. van der Heijden, Netherlands
Nana H. Overgaard, Denmark	Michael Weller, Switzerland

LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their applications in cancer medicine
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



Bristol-Myers Squibb



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano - Viganello
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 4 May 2018

09:00-09:15 15'	Historical introduction	
15'	Historical introduction	Rolf A. Stahel, CH
09:15-10:30 75'	SESSION 1 Essentials of tumour immunology	Chair: Rolf A. Stahel, CH
30'	From basic to tumour immunology for oncologists	Pedro Romero, CH
30'	From translational research to clinical application	John B.A.G. Haanen, NL
15'	Discussion	Faculty
10:30-11:10	Coffee break	
11:10-12:30 80'	SESSION 2 Essentials in immunotherapies	Chair: John B.A.G. Haanen, NL
40'	Immune Checkpoints - clinical use	Aurélien Marabelle, FR
25'	Adoptive T-Cell transfer	Inge-Marie Svane, DK
15'	Discussion	Faculty
12:30-13:30	Lunch	
13:30-15:00 90'	SESSION 3 Clinical development	Chair: Rolf A. Stahel, CH
25'	Ovarian cancer	Cristiana Sessa, CH
25'	Breast cancer	Giuseppe Curigliano, IT
25'	Bladder and renal cell cancer	Michiel S. van der Heijden, NL
15'	Discussion	Faculty
15:00-15:30	Coffee break	
15:30-16:30 60'	SESSION 4 Melanoma	Chair: Rolf A. Stahel, CH
25'	Immune Checkpoints	John B.A.G. Haanen, NL
25'	Combination therapies	John B.A.G. Haanen, NL
10'	Discussion	Faculty
16:30-18:00 90'	SESSION 5 Lung cancer, thoracic cancer and Gastro-Intestinal cancers	Chair: Rolf A. Stahel, CH
25'	Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer	Rolf A. Stahel, CH
25'	Immune Checkpoint Inhibitors in other thoracic malignancies	Solange Peters, CH
25'	Immunotherapy of GI cancers	Andrés Cervantes, ES
15'	Discussion	Faculty
19:30	Dinner	

Saturday, 5 May 2018

08:30-09:50 80'	SESSION 6 Audience cases	Chair: John B.A.G. Haanen, NL
8x10'	8 x Participants clinical case discussion	Faculty
09:50-10:35 45'	SESSION 7 Immunomonitoring and tumour antigens	Chair: Solange Peters, CH
30'	T-Cell recognition of cancer	Nana H. Overgaard, DK
15'	Discussion	Faculty
10:35-10:55	Coffee break	
10:55-12:00 65'	SESSION 8 Clinical development	Chair: Rolf A. Stahel, CH
25'	Haemato-oncology	Markus G. Manz, CH
25'	Glioblastoma	Michael Weller, CH
15'	Discussion	Faculty
12:00-12:40 40'	SESSION 9 Management of toxicities	Chair: Rolf A. Stahel, CH
25'	Management of toxicities	John B.A.G. Haanen, NL
15'	Discussion	Faculty
12:40-13:00 20'	General discussion	Rolf A. Stahel, CH
13:00-14:00	Lunch	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion